https://www.kitepharma.com/ 2024-05-09 weekly 1.0 https://www.kitepharma.com/compliance-program 2020-05-08 weekly 0.9 https://www.kitepharma.com/compliance-program/kite-pharma-health-care-compliance 2020-04-03 weekly 0.9 https://www.kitepharma.com/consumer-health-data-privacy-policy 2024-03-12 weekly 0.9 https://www.kitepharma.com/privacy-policy 2023-01-24 weekly 0.9 https://www.kitepharma.com/privacy-policy/french-translation 2020-06-22 weekly 0.9 https://www.kitepharma.com/privacy-policy/german-translation 2020-06-22 weekly 0.9 https://www.kitepharma.com/privacy-policy/greek-translation 2020-06-22 weekly 0.9 https://www.kitepharma.com/privacy-policy/italian-translation 2020-06-22 weekly 0.9 https://www.kitepharma.com/privacy-policy/polish-translation 2020-06-22 weekly 0.9 https://www.kitepharma.com/privacy-policy/spanish-translations 2022-10-20 weekly 0.9 https://www.kitepharma.com/social-media-guidelines 2022-04-22 weekly 0.9 https://www.kitepharma.com/terms-of-use 2020-05-05 weekly 0.9 https://www.kitepharma.com/about-us/our-mission 2023-07-12 weekly 0.9 https://www.kitepharma.com/about-us/our-story 2020-05-04 weekly 0.9 https://www.kitepharma.com/about-us/our-story/therapeutic-areas 2022-05-27 weekly 0.9 https://www.kitepharma.com/about-us/areas-of-focus 2025-06-16 weekly 0.9 https://www.kitepharma.com/about-us/leadership 2023-09-05 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/brian-heath 2025-01-13 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/cindy-perettie 2025-03-19 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/dominique-tonelli 2024-10-22 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/gallia-levy 2025-03-27 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/ibrahim-elhoussieny 2024-10-02 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/jason-carter 2023-10-02 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/joe-spiegler 2025-03-19 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/ken-takeshita 2021-01-29 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/kevin-cognetti 2025-03-24 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/kite-leader-page-test 2023-06-28 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/laura-alquist 2025-03-19 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/michelle-roth 2024-09-26 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/priti-hegde 2024-10-02 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/sarah-stephens 2025-07-14 weekly 0.9 https://www.kitepharma.com/about-us/leadership/kite-leadership-list/shelby-geyer 2025-03-24 weekly 0.9 https://www.kitepharma.com/about-us/kite-locations 2025-03-26 weekly 0.9 https://www.kitepharma.com/cell-therapy/cell-therapy-technology 2023-11-13 weekly 0.9 https://www.kitepharma.com/cell-therapy/cancer-treatments 2021-05-05 weekly 0.9 https://www.kitepharma.com/cell-therapy/pipeline 2023-07-14 weekly 0.9 https://www.kitepharma.com/cell-therapy/clinical-trials-and-access 2020-05-14 weekly 0.9 https://www.kitepharma.com/cell-therapy/clinical-trial-diversity 2024-01-22 weekly 0.9 https://www.kitepharma.com/cell-therapy/external-research-program 2020-05-14 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories 2024-11-25 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/rss 2024-11-25 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/emilys-experience 2024-11-25 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/chucks-experience 2024-11-26 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/celestes-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/julies-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/michael-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/kelly-experience 2023-07-12 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/shons-experience 2024-02-14 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/brandens-experience 2023-06-02 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/david-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/eleonora-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/marcus-experience 2023-05-29 weekly 0.9 https://www.kitepharma.com/patient-resources/patient-stories/chip-experience 2024-11-25 weekly 0.9 https://www.kitepharma.com/patient-resources/find-a-treatment-center 2025-06-10 weekly 0.9 https://www.kitepharma.com/news/newsroom 2025-05-28 weekly 0.9 https://www.kitepharma.com/news/press-releases 2025-12-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/rss 2025-07-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refrac 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2017/12/kite-announces-data-from-zuma-3-study-of-kte-c19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2017/12/kite-announces-longterm-data-from-pivotal-zuma1-study-of-yescarta-axicabtagene-ciloleucel-in-patients-with-refractory-large-bcell-lymphoma 2022-10-26 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/1/kite-announces-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-and-pfizers-utomilumab-in-large 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/10/kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigen-reactive-t-cell-recept 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/11/gilead-to-present-latest-scientific-research-in-hematologic-malignancies-and-solid-tumors-at-ash-2018 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/12/kite-announces-twoyear-data-for-yescarta-axicabtagene-ciloleucel-in-patients-with-refractory-large-bcell-lymphoma 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/12/kite-announces-updated-data-from-zuma-3-study-of-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2020-07-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/2/kite-a-gilead-company-and-sangamo-therapeutics-announce-collaboration-to-develop-nextgeneration-engineered-cell-therapies-for-the-treatment-of-canc 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/5/kite-announces-new-worldwide-facilities-and-expanded-collaboration-with-national-cancer-institute-to-support-cell-therapy-pipeline 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/6/european-chmp-adopts-positive-opinion-for-yescarta-axicabtagene-ciloleucel-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-o 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/6/kite-announces-initial-results-from-a-phase-1-study-of-t-cell-receptor-tcr-cell-therapy-in-hpv16positive-solid-tumors 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/6/kite-announces-new-data-analyses-for-car-t-therapy-in-patients-with-blood-cancers-at-the-2018-american-society-of-clinical-oncology-meeting 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/7/kite-and-gadeta-announce-strategic-collaboration-to-advance-gamma-delta-t-cell-receptor-technology-for-solid-tumors 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/7/michael-amoroso-to-join-kite-as-senior-vice-president-and-head-of-worldwide-commercial-cell-therapy 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2018/8/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-o 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/11/industry-veterans-appointed-to-head-the-global-technical-operations-and-clinical-development-organizations-at-kite 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/11/kite-to-present-new-data-from-industry-leading-cell-therapy-portfolio-at-ash-2019 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/12/kite-and-kiniksa-pharmaceuticals-announce-clinical-collaboration-evaluating-investigational-combination-of-yescarta-and-mavrilimumab-in-relapsed-or-r 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/12/kite-and-the-cibmtr-present-positive-findings-from-realworld-use-of-yescarta-axicabtagene-ciloleucel-in-relapsed-or-refractory-large-bcell-lymph 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/12/kite-announces-long-term-data-from-zuma-1-showing-approximately-half-of-refractory-large-b-cell-lymphoma-patients-were-alive-three-years-after-yescart 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/12/kite-presents-positive-results-from-pivotal-zuma-2-trial-in-relapsed-or-refractory-mantle-cell-lymphoma 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/12/kite-submits-biologics-license-application-to-us-food-and-drug-administration-for-companys-second-car-t-cell-therapy 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/4/kite-announces-plans-for-new-state-of-the-art-facility-to-expand-cell-therapy-production-capabilities 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/5/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-r 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/5/kite-to-present-new-data-from-leading-cell-therapy-portfolio-at-asco-2019 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/6/kite-announces-end-of-phase-1-zuma-3-results-for-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/6/kite-announces-new-yescarta-data-from-zuma-1 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/7/gilead-appoints-christi-l-shaw-as-chief-executive-officer-of-kite 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/7/gilead-sciences-announces-second-quarter-2019-financial-results 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2019/7/kite-announces-plans-to-bolster-industry-leading-cell-therapy-manufacturing-capabilities-with-new-viral-vector-facility 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/1/european-medicines-agency-validates-kites-marketing-application-for-companys-second-car-t-cell-therapy 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/10/european-chmp-adopts-positive-opinion-for-kites-kte-x19-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma 2020-10-16 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/10/gilead-sciences-announces-third-quarter-2020-financial-results 2020-10-28 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/11/gilead-and-kite-to-share-latest-scientific-advances-in-hematologic-malignancies-at-ash-2020 2020-11-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/12/kites-tecartus-ktex19-granted-conditional-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-in-europe 2020-12-16 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/12/new-data-for-tecartustm-demonstrate-durable-responses-at-one-year-follow-up-in-relapsed-or-refractory-mantle-cell-lymphoma 2020-12-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/12/new-four-year-data-show-long-term-survival-in-patients-with-large-b-cell-lymphoma-treated-with-yescarta-in-zuma-1-trial 2020-12-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/12/yescarta-is-first-car-t-cell-therapy-to-demonstrate-high-response-rates-and-durable-clinical-benefit-in-a-pivotal-indolent-non-hodgkin-lymphoma-study 2020-12-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/12/yescarta-shows-positive-results-as-a-first-line-treatment-for-patients-with-high-risk-large-b-cell-lymphoma 2020-12-06 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/2/us-fda-grants-priority-review-for-kites-ktex19-biologics-license-application-bla-in-relapsed-or-refractory-mantle-cell-lymphoma 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/4/gilead-kite-and-onkoinnate-announce-research-collaboration-to-discover-cancer-immunotherapies-focused-on-natural-killer-nk-cells 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/4/gilead-sciences-announces-first-quarter-2020-financial-results 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/4/kite-licenses-antibodies-and-establishes-collaboration-with-teneobio-in-multiple-myeloma 2020-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/5/gilead-and-kite-continue-to-advance-next-generation-cancer-therapies-at-2020-american-society-of-clinical-oncology-annual-meeting 2020-05-14 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/5/yescarta-axicabtagene-ciloleucel-demonstrates-high-rates-of-response-in-relapsed-or-refractory-indolent-nonhodgkin-lymphoma 2020-05-29 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/6/kite-receives-european-medicines-agency-approval-for-car-t-cell-therapy-manufacturing-facility-in-europe 2020-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/7/gilead-sciences-announces-second-quarter-and-first-half-2020-financial-results 2020-07-30 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma 2020-07-24 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/9/kite-and-hifibio-therapeutics-partner-to-discover-novel-targets-and-antibodies-against-acute-myeloid-leukemia 2020-09-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2020/9/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-yescarta-in-relapsed-or-refractory-indolent-nonhodg 2020-09-04 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/1/francesco-m-marincola-joins-kite-as-worldwide-head-of-cell-therapy-research 2021-01-19 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/1/kite-and-oxford-biotherapeutics-establish-cell-therapy-research-collaboration-in-blood-cancers-and-solid-tumors 2021-01-06 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/10/us-fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemia 2021-10-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/11/gilead-and-kite-oncology-demonstrate-broad-leadership-in-cell-therapy-and-expanding-blood-cancer-pipeline 2021-11-04 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/12/daiichi-sankyo-authorizes-the-first-yescarta-axicabtagene-ciloleucel-car-tcell-therapy-treatment-site-in-japan 2021-12-16 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/12/yescarta-car-t-cell-therapy-quadruples-median-event-free-survival-duration-over-standard-of-care-in-second-line-relapsed-or-refractory-large-b-cell-l 2021-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/12/yescarta-demonstrates-durable-two-year-clinical-benefit-in-adults-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-including-follicular-lymp 2021-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/12/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refract 2021-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/12/yescarta-zuma12-study-demonstrates-78-complete-response-rate-as-part-of-firstline-treatment-in-newly-diagnosed-highrisk-large-bcell-lymphoma 2021-12-13 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/2/kite-announces-new-zuma-1-cohort-analysis-evaluating-prophylactic-corticosteroid-use-with-yescarta-in-patients-with-relapsed-or-refractory-large-b-ce 2021-02-10 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/2/kite-appoints-frank-neumann-as-worldwide-head-of-clinical-development 2021-02-08 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/3/us-fda-approves-yescarta-for-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy 2021-03-06 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/4/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-tecartus-in-adult-patients-with-relapsed-or-refracto 2021-04-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/5/gilead-kite-oncology-to-present-transformative-science-from-growing-portfolio-at-asco-2021 2021-05-19 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/6/kite-and-shoreline-biosciences-enter-into-strategic-partnership-to-develop-novel-allogeneic-cell-therapies 2021-06-17 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/6/kite-announces-yescarta-car-tcell-therapy-improved-eventfree-survival-by-60-over-chemotherapy-plus-stem-cell-transplant-in-secondline-relapsed-or 2021-06-29 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/6/kite-joint-venture---fosun-kite---gains-the-first-car-t-cell-therapy-approval-in-china 2021-06-23 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/6/kites-tecartus-demonstrates-high-response-rate-in-adults-with-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemia-earning-priority-review-des 2021-06-04 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/6/longer-term-data-for-kites-yescarta-in-relapsed-or-refractory-follicular-lymphoma-demonstrate-substantial-survival-improvement-over-current-therapie 2021-06-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/7/biontech-to-acquire-kites-neoantigen-tcr-cell-therapy-rd-platform-and-manufacturing-facility-in-gaithersburg-md 2021-07-19 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/8/biontech-completes-acquisition-of-kites-neoantigen-tcr-cell-therapy-rd-platform-and-manufacturing-facility-in-gaithersburg-maryland 2021-08-04 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/8/kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell-therapies-for-cancer 2021-08-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2021/9/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-earlier-use-of-yescarta-in-large-bcell-lymphoma 2021-10-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/1/us-fda-approves-new-label-update-for-car-tcell-therapy-yescarta-showing-prophylactic-steroid-use-improves-management-of-cytokine-release-syndrome 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/10/kite-and-refuge-biotechnologies-announce-exclusive-license-agreement-for-investigational-gene-expression-platform-for-blood-cancers 2022-10-20 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/10/kite-receives-us-fda-approval-of-viral-vector-manufacturing-facility-in-southern-california-to-produce-commercial-product 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/10/kites-yescarta-first-car-t-cell-therapy-to-receive-european-marketing-authorization-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-gra 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/11/gilead-and-kite-oncology-demonstrate-transformative-impact-of-cell-therapy-and-promise-of-blood-cancer-portfolio-at-ash-2022 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/body-of-evidence-grows-from-zuma-7-study-supporting-initial-treatment-with-kites-yescarta-car-t-cell-therapy-for-patients-with-relapsed-or-refractor 2022-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma 2022-12-09 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/kite-and-daiichi-sankyo-announce-changes-to-yescarta-car-t-cell-therapy-licensing-agreement-in-japan 2022-12-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancer 2022-12-20 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/new-analyses-of-kites-tecartus-car-tcell-therapy-provide-additional-evidence-supporting-overall-survival-and-durability-of-response 2022-12-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/threeyear-followup-analysis-of-kites-yescarta-car-tcell-therapy-zuma5-trial--52-of-patients-with-indolent-lymphomas-continued-to-have-ongoin 2022-12-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/time-to-car-t-cell-therapy-may-impact-outcomes-for-patients-with-relapsedrefractory-large-b-cell-lymphoma-in-new-cibmtr-analysis 2022-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/12/yescarta-now-approved-in-japan-for-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma 2022-12-22 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/4/kite-receives-us-fda-approval-of-new-stateoftheart-car-tcell-therapy-manufacturing-facility-in-maryland 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/4/yescarta-receives-us-fda-approval-as-first-car-tcell-therapy-for-initial-treatment-of-relapsed-or-refractory-large-bcell-lymphoma-lbcl 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/5/gilead-and-kite-oncology-to-highlight-advances-supporting-new-innovations-in-cancer-care-at-the-asco-annual-meeting 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/6/kites-car-t-cell-therapy-yescarta-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/6/subanalyses-of-landmark-zuma7-trial-reinforce-yescarta-car-tcell-therapy-superiority-over-standard-of-care-soc-as-initial-treatment-for-patients 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/6/tecartus-car-t-cell-therapy-demonstrates-strong-overall-survival-rates-and-continued-durable-responses-in-long-term-follow-up-of-two-pivotal-studies 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/6/yescarta-car-t-cell-therapy-demonstrates-consistent-survival-outcomes-and-safety-in-real-world-setting-regardless-of-race-and-ethnicity 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/7/kites-car-tcell-therapy-tecartus-receives-positive-chmp-opinion-in-relapsed-or-refractory-acute-lymphoblastic-leukemia-rr-all 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/9/kites-car-t-cell-therapy-tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2022/9/kites-car-t-cell-therapy-yescarta-first-in-europe-to-receive-positive-chmp-opinion-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-gra 2022-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/1/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma 2023-01-30 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/10/gilead-and-kite-oncology-present-important-new-data-across-multiple-difficult-to-treat-cancers-at-esmo-congress-2023 2023-10-31 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/10/kite-and-epic-bio-announce-collaboration-to-develop-new-therapies-for-cancer 2023-11-02 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/11/gilead-and-kite-oncology-present-data-demonstrating-car-t-cell-therapy-survival-benefit-and-showcasing-latest-advances-in-blood-cancer-portfolio-at-as 2023-11-29 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/11/kite-and-arcellx-announce-expansion-in-strategic-partnership 2023-11-15 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/12/analyses-of-kites-yescartacar-t-cell-therapy-support-curative-potential-in-patients-with-non-hodgkin-lymphomas 2023-12-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/12/long-term-data-for-kites-yescarta-car-t-cell-therapy-presented-at-ash-2023-demonstrate-high-rate-of-durable-response-in-patients-with-high-risk-larg 2023-12-11 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/12/new-analyses-presented-at-ash-2023-support-the-potential-long-term-response-and-safety-of-kites-tecartus-in-patients-with-aggressive-blood-cancers 2023-12-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/12/us-fda-approves-label-update-for-kites-yescarta-car-tcell-therapy-to-include-overall-survival-data 2024-10-02 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/2/gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-results 2023-02-02 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/2/kite-completes-acquisition-of-tmunity 2023-02-22 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/2/kites-tecartus-car-t-cell-therapy-demonstrates-overall-survival-benefit-in-three-year-follow-up-of-pivotal-zuma-3-trial-in-relapsedrefractory-b-cel 2023-02-09 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/3/kites-yescarta-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsedrefract 2023-07-12 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/5/gilead-appoints-cindy-perettie-executive-vice-president-of-kite 2023-06-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/5/gilead-and-kite-oncology-to-showcase-advances-across-the-pipeline-aiming-to-address-unmet-needs-in-cancer-care-at-asco-2023 2023-06-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/6/gilead-and-kite-oncology-demonstrate-growing-hematology-pipeline-and-strength-of-leading-cell-therapy-portfolio-at-eha 2023-06-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/6/kite-announces-completion-of-marketing-authorization-transfer-for-yescarta-car-t-cell-therapy-in-japan 2023-06-22 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/6/kites-tecartus-car-tcelltherapy-demonstrates-78-complete-response-rate-and-90-overall-response-rate-in-largest-realworld-evidence-analysis-for-r 2023-06-13 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/6/kites-yescarta-car-t-cell-therapy-demonstrates-significantly-longer-overall-survival-versus-standard-of-care-as-initial-treatment-of-relapsedrefrac 2023-06-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2023/9/kites-car-t-cell-therapy-yescarta-demonstrates-high-response-rate-and-durable-remission-in-alycante-study-as-initial-treatment-for-transplant-inelig 2024-10-02 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/1/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-tcell-therapy 2024-01-30 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/11/kite-to-highlight-industryleading-car-tcell-therapy-portfolio-at-ash-2024-including-positive-survival-outcomes-in-both-clinical-trials-and-the-real 2024-11-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/12/kite-presents-new-data-underscoring-curative-potential-of-yescarta-in-relapsedrefractory-large-b-cell-lymphoma-at-ash 2024-12-08 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/12/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-term-survival-after-five-years-in-patients-with-relapsedrefractory-non-hod 2024-12-09 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/12/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024-reinforce-durable-efficacy-and-survival-benefits 2024-12-09 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/5/gilead-and-kite-oncology-to-highlight-broad-and-diverse-oncology-portfolio-at-asco-2024 2024-05-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/5/kite-and-arcellx-continue-momentum-with-advances-in-anito-cel-multiple-myeloma-program 2024-05-09 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/5/kite-data-at-eha-2024-demonstrate-positive-patient-outcomes-and-advances-in-delivery-of-car-t-cell-therapy 2024-05-14 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/6/encouraging-new-data-presented-on-kites-yescarta-for-relapsedrefractory-central-nervous-system-lymphoma 2024-06-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/6/kites-tecartus-demonstrates-sustained-overall-survival-in-adult-patients-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia 2024-06-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2024/6/new-kite-clinical-research-and-real-world-evidence-for-yescarta-demonstrate-benefit-from-earlier-lines-of-treatment 2024-11-05 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/10/gilead-and-kite-reinforce-bold-commitment-to-transform-cancer-care-with-new-data-at-esmo-2025 2025-10-13 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/11/gilead-and-kite-showcase-continued-progress-in-transforming-blood-cancer-care-with-new-cell-therapy-data-at-ash-2025 2025-11-03 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/12/kite-announces-new-data-for-pivotal-immagine1-study-at-ash-2025-highlighting-anitocels-opportunity-in-relapsed-or-refractory-multiple-myeloma 2025-12-06 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/12/kites-next-generation-bicistronic-car-t-cell-therapies-show-encouraging-phase-1-results-in-relapsedrefractory-b-cell-lymphoma-in-new-data-at-ash-202 2025-12-06 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/12/yescarta-delivers-consistent-safety-efficacy-and-quality-of-life-benefits-across-broad-range-of-relapsedrefractory-large-bcell-lymphoma-patients 2025-12-07 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/5/gilead-and-kite-announce-presentation-of-transformative-data-in-1l-metastatic-triplenegative-breast-cancer-updated-results-in-multiple-myeloma-and-e 2025-05-15 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/6/kite-presents-new-real-world-data-supporting-use-of-potentially-curative-yescarta-in-outpatient-care-setting-for-patients-with-relapsedrefractory-la 2025-06-01 weekly 0.9 https://www.kitepharma.com/news/press-releases/2025/8/kite-to-acquire-interius-biotherapeutics-to-advance-in-vivo-platform 2025-08-21 weekly 0.9 https://www.kitepharma.com/news/company-statements 2023-07-11 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-appoints-gallia-levy-md-phd-as-global-head-of-clinical-development-and-laura-alquist-as-global-head-of-technical-operations 2024-10-15 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-receives-us-fda-regenerative-medicine-advanced-therapy-designation 2024-10-03 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-appoints-priti-hegde-as-global-head-of-research 2023-10-02 weekly 0.9 https://www.kitepharma.com/news/company-statements/nice-recommends-expanded-and-earlier-use-of-kite-car-t-cell-therapy-to-treat-certain-types-of-blood-cancer 2023-06-22 weekly 0.9 https://www.kitepharma.com/news/company-statements/kites-yescarta-first-car-t-cell-therapy-to-receive-health-canada-authorization-for-use-as-initial-treatment-of-relapsed-refractory-large-b-cell-lymphoma 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/christi-shaw-to-depart-gilead-and-kite-leadership-end-of-q1 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-yescarta-is-first-car-t-cell-therapy-recommended-for-routine-use--in-england-united-kingdom 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-expands-cell-therapy-manufacturing-operations-in-maryland 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/supreme-court-denied-juno-appeal-request-in-juno-vs-kite-case 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-receives-us-food-and-drug-administration-fda-orphan-drug-designation-for-kite-222-for-acute-myeloid-leukemia 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-launches-car-t-cell-therapy-operations-in-brazil,-singapore-and-saudi-arabia 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-announces-u,-d-,s,-d-,-fda-clearance-of-investigational-new-drug-application-for-kite-363,-a-dual-targeting-car-t-cell-therapy-candidate-for-large-b-cell-lymphoma 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-yescarta-axicabtagene-ciloleucel-car-t-cell-therapy-now-widely-available-and-publicly-funded-for-patients-in-australia-with-four-types-of-aggressive-non-hodgkin-lymphoma 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/company-statements/kite-announces-u,-d-,s,-d-,-fda-clearance-of-investigational-new-drug-application-for-kite-222,-an-anti-cll-1-car-t-cell-therapy-candidate-for-acute-myeloid-leukemia- 2023-06-07 weekly 0.9 https://www.kitepharma.com/news/media-kit 2023-07-11 weekly 0.9 https://www.kitepharma.com/careers/careers-at-kite 2024-05-30 weekly 0.9 https://www.kitepharma.com/careers/veteran-careers-at-kite 2026-01-29 weekly 0.9 https://www.kitepharma.com/careers/early-talent-programs-at-kite 2023-11-17 weekly 0.9 https://www.kitepharma.com/careers/culture-and-benefits 2023-11-10 weekly 0.9 https://www.kitepharma.com/utility/investor-relations 2020-05-04 weekly 0.9 https://www.kitepharma.com/utility/contact-us 2021-01-22 weekly 0.9 https://www.kitepharma.com/search 2020-04-08 weekly 0.9 https://www.kitepharma.com/sandbox/contactlist 2020-05-12 weekly 0.9